Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tom Hedman, PhD Founder. Snoring: 48% of men, 34% of women & growing (obesity, allergies, aging) Sleep deprivation – snorer; sleep cycle disruption, stress.

Similar presentations


Presentation on theme: "Tom Hedman, PhD Founder. Snoring: 48% of men, 34% of women & growing (obesity, allergies, aging) Sleep deprivation – snorer; sleep cycle disruption, stress."— Presentation transcript:

1 Tom Hedman, PhD Founder

2 Snoring: 48% of men, 34% of women & growing (obesity, allergies, aging) Sleep deprivation – snorer; sleep cycle disruption, stress – family Can lead to OSA Obstructive Sleep Apnea: Breathing interrupted during sleep by obstruction of the airway US: 4.2% age 16 & older, ~10 million adults & growing Over age 65: 28% of men, 24% of women

3 Injectable Collagen Crosslinking Immediate effect Permanent covalent bonds Low cost – high profit margin NEXT NEXT NEXT - Nonsurgical EXogenous Crosslink Therapy genipin

4 Equine Soft Palate Collagen Mapping

5 Wind Tunnel Video: Experiments with untreated (brown) and treated (dark blue) equine soft palates

6 69% Reduction in Maximum Transient Deformation

7 51% Reduction in Steady State Vibration Amplitude Virtual Elimination of Low Frequency – High Energy Vibration

8 Competitive Advantage: Primary competition: Primary competition: Existing surgical treatments Existing surgical treatments Oral appliances that alter geometry of pharynx/ upper airway (incl. CPAP) Oral appliances that alter geometry of pharynx/ upper airway (incl. CPAP) Minimally invasive stiffening procedures Minimally invasive stiffening procedures Competition: inconsistent, limited or temporary effectiveness; invasive (surgery), inconvenient or uncomfortable (oral appliances, CPAP); Competition: inconsistent, limited or temporary effectiveness; invasive (surgery), inconvenient or uncomfortable (oral appliances, CPAP); Existing and emerging minimally invasive procedures rely on formation of scar tissue – which is inherently disorganized, weak, easily degraded Existing and emerging minimally invasive procedures rely on formation of scar tissue – which is inherently disorganized, weak, easily degraded NEXT – Effective! Preserves matrix integrity, strengthens tissue NEXT – Effective! Preserves matrix integrity, strengthens tissue

9 Patent Portfolio 10 US and 7 international patents issued or in condition for allowance Snoring – Obstructive Sleep Apnea specific patent pending Additional 20+ US and international patents pending Issued Patents USForeign 10/230,671 Found in condition for allowance Australia 2002335683 7,435,722Canada 2,458,821 8,153,600Australia 2004268628 8,022,101Japan 2006-524909 8,119,599Canada 2,536,415 8,198,248Korea 8,211,938Australia 2010266306 Claims found allowable 8,283,322 8,450,276 12/966,812 Found in condition for allowance

10 Over 10 years experience with new business development; successful in funding and market launch of a host of consumer, commercial, and medical/chemical products Formerly VP-Product Management & Marketing for Landmark Earth Solutions (newly formed and wholly owned subsidiary of Leggett & Platt); held senior positions with Robert Bosch, The Coleman Company, Vermont American, and Char-Broil MBA - Bellarmine University, BS - Florida State Univ., adjunct faculty - Indiana Wesleyan Univ. Lyle T. Hawkins CEO/President Founder of 7 biotech companies, 25+ years in biomechanics research, led 1 st North American artificial disc design/ development team Graduate of MIT, & Ph.D. in Bioengineering from Strathclyde University Currently Associate Professor at University of Kentucky Tom Hedman, PhD Founder, CSO 20+ years in medical device regulatory, clinical, and quality functions Successful in bringing a crosslinking technology through FDA as Class III Med. Dev. Worked at Baxter, Cordis J&J, CryoLife (Dir), Percutaneous Valve Technologies (Sr. Dir. – Head RA/CA), and AtriCure (VP) with successful FDA approval track record Maintains her RAPS Regulatory Affairs Certification Elsa Abruzzo VP Reg./Clinical Affairs Ind.& Manuf. Engineering Management Team

11 Funding required for 2014-2015: $250k ($1.25M initial valuation) Patent prosecution and annuity costs Gap funding R&D – between NIH SBIR Phase I and Phase II grants Partial support for CEO/President – business plan development, market research Contact Tom Hedman for more information: thedman@restinnovations.com


Download ppt "Tom Hedman, PhD Founder. Snoring: 48% of men, 34% of women & growing (obesity, allergies, aging) Sleep deprivation – snorer; sleep cycle disruption, stress."

Similar presentations


Ads by Google